Affiliation:
1. Hind Institute of Medical Sciences, Barabanki, Lucknow, India
Abstract
C-peptide, a key biomarker for beta-cell function in diabetes, has potential in understanding and managing the disease, though its application in type 2 diabetes is limited by insufficient evidence. It provides insights into endogenous insulin secretion and faces challenges in measurement standardization. In type 1 diabetes, C-peptide levels reflect beta cell loss, while in type 2 diabetes, higher levels indicate a higher risk of progression. Preserved C-peptide levels differentiate maturity onset diabetes of the young (MODY) from type 1 diabetes. C-peptide is also associated with gestational diabetes risk. It shows correlations with improved outcomes in type 1 diabetes but controversial associations with macrovascular complications. Despite its promise, standardization, interpretation, and utilization issues require further research and trials for personalized treatments in diabetes.
Publisher
IP Innovative Publication Pvt Ltd
Reference20 articles.
1. Leighton E, Sainsbury CA, Jones GC, A practical review of C-peptide testing in diabetes..Diab Ther 2017;8(3):475-87
2. Maddaloni E, Bolli GB, Frier BM, Little RR, Leslie RD, Pozzilli P, C-peptide determination in the diagnosis of type of diabetes and its management: A clinical perspective.Diab Obes Metab 2022;24(10):1912-38
3. Jones AG, Hattersley AT, The clinical utility of C-peptide measurement in the care of patients with diabetes..Diab Med 2013;30(7):803-20
4. Leighton E, Sainsbury CA, Jones GC, A practical review of C-peptide testing in diabetes..Diab Ther 2017;8(2):475-87
5. Hörber S, Orth M, Fritsche A, Peter A, Comparability of C-Peptide Measurements-Current Status and Clinical Relevance.Exp Clin Endocrinol Diab 2023;8(3):475-87